These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32061473)

  • 21. Drug-induced liver steatosis in patients with HIV infection.
    Gervasoni C; Cattaneo D; Filice C; Galli M;
    Pharmacol Res; 2019 Jul; 145():104267. PubMed ID: 31077811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.
    Morris-Stiff G; Tan YM; Vauthey JN
    Eur J Surg Oncol; 2008 Jun; 34(6):609-14. PubMed ID: 17764887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
    Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
    BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of systemic chemotherapy on the liver.
    Ramadori G; Cameron S
    Ann Hepatol; 2010; 9(2):133-43. PubMed ID: 20526005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs and steatohepatitis.
    Farrell GC
    Semin Liver Dis; 2002; 22(2):185-94. PubMed ID: 12016549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
    Khan AZ; Morris-Stiff G; Makuuchi M
    J Hepatobiliary Pancreat Surg; 2009; 16(2):137-44. PubMed ID: 19093069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 Oct; 354(9186):1299-300. PubMed ID: 10520659
    [No Abstract]   [Full Text] [Related]  

  • 28. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.
    Bessone F; Dirchwolf M; Rodil MA; Razori MV; Roma MG
    Aliment Pharmacol Ther; 2018 Nov; 48(9):892-913. PubMed ID: 30194708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
    Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
    Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversibility of chemotherapy-related liver injury.
    Vigano L; De Rosa G; Toso C; Andres A; Ferrero A; Roth A; Sperti E; Majno P; Rubbia-Brandt L
    J Hepatol; 2017 Jul; 67(1):84-91. PubMed ID: 28284915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LiMAx Test Improves Diagnosis of Chemotherapy-Associated Liver Injury Before Resection of Colorectal Liver Metastases.
    Lock JF; Westphal T; Rubin T; Malinowski M; Schulz A; Jara M; Bednarsch J; Stockmann M
    Ann Surg Oncol; 2017 Sep; 24(9):2447-2455. PubMed ID: 28516292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy-Associated Hepatotoxicities.
    White MA; Fong Y; Singh G
    Surg Clin North Am; 2016 Apr; 96(2):207-17. PubMed ID: 27017860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatty liver and drugs: the two sides of the same coin.
    Miele L; Liguori A; Marrone G; Biolato M; Araneo C; Vaccaro FG; Gasbarrini A; Grieco A
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(1 Suppl):86-94. PubMed ID: 28379591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases.
    Reissfelder C; Brand K; Sobiegalla J; Rahbari NN; Bork U; Schirmacher P; Büchler MW; Weitz J; Koch M
    Surgery; 2014 Feb; 155(2):245-54. PubMed ID: 24314883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis.
    Pavlik L; Regev A; Ardayfio PA; Chalasani NP
    Drug Saf; 2019 Jun; 42(6):701-711. PubMed ID: 30762163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic review of drug-induced steatohepatitis.
    Schumacher JD; Guo GL
    Toxicol Appl Pharmacol; 2015 Nov; 289(1):40-7. PubMed ID: 26344000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies.
    Amacher DE
    Toxicology; 2011 Jan; 279(1-3):10-8. PubMed ID: 20974209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An animal model for chemotherapy-associated steatohepatitis and its prevention by the oral administration of fatty acid bile acid conjugate.
    Keizman D; Maimon N; Ish-Shalom M; Buchbut D; Inbar M; Klein B; Bernheim J; Goldiner I; Leikin-Frenkel A; Konikoff F
    Cancer; 2010 Jan; 116(1):251-5. PubMed ID: 19890960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hepatic steatosis : Differential diagnostics and current aspects].
    Canbay A; Gerken G; Bechmann LP
    Internist (Berl); 2016 Sep; 57(9):879-92. PubMed ID: 27510334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatoprotective effect of pioglitazone in cases of chemotherapy induced steatohepatitis.
    Celik S; Kartal K; Ozseker H; Hayran M; Hamaloglu E
    Chirurgia (Bucur); 2015; 110(1):49-55. PubMed ID: 25800316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.